The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Gepotidacin is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing rising drug resistance. Phase 3 trials showed gepotidacin's non-inferiority to nitrofurantoin ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or uUTIs, successfully and safely.

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years ... In these studies, Blujepa was compared with nitrofurantoin, a leading treatment for uncomplicated UTIs.

Blujepa sets itself apart from nitrofurantoin as ... To put it simply, the drug is designed to specifically inhibit bacterial DNA in the E. coli class, which causes the majority of UTI infections ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial ... to receive gepotidacin 1500mg twice daily or nitrofurantoin 100mg twice daily for 5 days.

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.

47% in patients treated with nitrofurantoin ... the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections ...